On June 16, 2021, the Board of Directors of Athira Pharma, Inc. determined to place Leen Kawas, Ph.D., President of the Company, on temporary paid leave pending a review of actions stemming from doctoral research Dr. Kawas conducted while at Washington State University. Dr. Kawas continues to serve as a member of the Board. On the same day, the Board determined that during Dr. Kawas’s leave and effective immediately, Mark Litton, Ph.D., MBA, the Company’s Chief Operating Officer, would continue in that role but would also assume the day-to-day responsibilities of president.